We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The most recent trading session ended with Bristol Myers Squibb (BMY - Free Report) standing at $53.28, reflecting a -0.19% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 1.03%. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 1.51%.
Shares of the biopharmaceutical company witnessed a gain of 9.75% over the previous month, beating the performance of the Medical sector with its gain of 2.1% and the S&P 500's gain of 3.21%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. It is anticipated that the company will report an EPS of $1.53, marking a 25.37% fall compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.46 billion, up 1.11% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.61 per share and a revenue of $46.11 billion, signifying shifts of -11.98% and +2.44%, respectively, from the last year.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.29% higher. Bristol Myers Squibb currently has a Zacks Rank of #4 (Sell).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 8.08. For comparison, its industry has an average Forward P/E of 21.72, which means Bristol Myers Squibb is trading at a discount to the group.
Also, we should mention that BMY has a PEG ratio of 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.61 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
The most recent trading session ended with Bristol Myers Squibb (BMY - Free Report) standing at $53.28, reflecting a -0.19% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 1.03%. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 1.51%.
Shares of the biopharmaceutical company witnessed a gain of 9.75% over the previous month, beating the performance of the Medical sector with its gain of 2.1% and the S&P 500's gain of 3.21%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. It is anticipated that the company will report an EPS of $1.53, marking a 25.37% fall compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.46 billion, up 1.11% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.61 per share and a revenue of $46.11 billion, signifying shifts of -11.98% and +2.44%, respectively, from the last year.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.29% higher. Bristol Myers Squibb currently has a Zacks Rank of #4 (Sell).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 8.08. For comparison, its industry has an average Forward P/E of 21.72, which means Bristol Myers Squibb is trading at a discount to the group.
Also, we should mention that BMY has a PEG ratio of 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.61 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.